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Abstract:  Seven norsesterterpene peroxides: epimuqubilin A (1), muqubilone B (2), 
unnamed cyclic peroxide ester (3), epimuqubilin B (4), sigmosceptrellin A methyl ester (5), 
sigmosceptrellin A (6), and sigmosceptrellin B methyl ester (7), isolated from the marine 
sponge Latrunculia sp., were examined with regard to their effects on nitric oxide (NO) 
production in lipopolysaccharide (LPS)-activated murine macrophage RAW 264.7 cells. 
The results indicated epimuqubilin A (1) possessed potent NO inhibitory activity against 
lipopolysaccharide (LPS)-induced nitric oxide release with an IC50 value of 7.4 µM, a level 
three times greater than the positive control, L-N
G-monomethyl arginine citrate, followed 
by 6 (sigmosceptrellin A, IC50 = 9.9 µM), whereas other compounds exhibited only modest 
activity (Table 1). These compounds did not show appreciable cytotoxicity at their IC50 
values for NO–inhibitory activity. The structure–activity upon NO inhibition could be 
summarized as follows: (1) a monocyclic carbon skeleton framework was essential for 
activity, (2) free acids gave higher activity, (3) the orientation of H3-22 with an equatorial 
position increased activity, and (4) a bicyclic structure reduced activity. This is the first 
report of a norsesterterpene peroxide with NO–inhibitory activity. In addition, compounds 
1–7 were also evaluated for their inhibitory activities in the yeast glycogen synthase 
kinase-3β assay. In summary, several norsesterterpene peroxides showed novel biological 
activities of inhibition in NO production, suggesting that these might provide leads for  
anti-inflammatory or cancer chemopreventive agents. 
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1. Introduction  
Sesterterpenes isolated from marine organisms are often modified by the loss or addition of one or 
more carbon units. Norsesterterpene peroxides are characterized with a 2-substituted propionic acid or 
methyl propionate group attached to a 1,2-dioxane ring at the C-3 position.  
Marine sponges of the Latrunculiidae family, which include the genera Sigmosceptrella [1,2], 
Latrunculia [3,4] and Diacarnus [5,6], have proven to be a rich source of norterpene cyclic peroxides, 
a novel class of bioactive marine metabolites. Sponges of the genus Latrunculia have a variety of the 
biosynthetically diverse secondary metabolites. The Red Sea sponge Latrunculia magnifica has been 
shown to contain macrocyclic thiazoles [7], while New Zealand, Australian, and Argentine species of 
Latrunculia have been shown to contain a variety of peptides and nitrogen-containing metabolites  
[8–12]. On the other hand, Australian Latrunculia species have been shown to be a rich source of 
novel norterpene acids and peroxides [3,4,13]. Interest has been focused on terpene peroxides as they 
frequently posses a vast array of biological activities such as ichthyotoxicity [1,2], antimicrobial [4], 
antitumor [6], cytotoxicity [5,14], sea urchin egg cell division inhibitory properties [15], antiviral [16],
 
antitoxoplasmodic [16], and antimalarial activities [16]. In spite of the number of studies that have 
been performed, there has been no investigation of the anti-inflammatory activity of the norterpenoids.  
Inflammation is the protective process of microcirculation in the host against a wide range of 
injuries caused by physical force, irradiation, extreme temperature, irritants and mostly infectious 
pathogens. However, dysregulated and perpetual inflammation may cause various pathophysiological 
conditions including gastritis, esophagitis, hepatitis, atherosclerosis, as well as cancer [17,18]. 
Macrophages are involved in chronic inflammation by producing various inflammatory mediators 
including cytokines, chemokines, interferon, colony-stimulating factors, lysozymes, proteases, growth 
factors, eicosanoids, and nitric oxide (NO) [19,20]. Among these, NO is excessively generated by one 
of pro-inflammatory enzymes, iNOS, and consequently results in diverse diseases and including 
asthma, arthritis, multiple sclerosis, colitis, psoriasis, neurodegenerative disorders, tumor development 
and transplant rejection of septic shock [21]. Therefore, it is of interest to find new inhibitors of  
NO production.  
Glycogen synthase kinase-3β (GSK-3β) is a serine/threonine kinase found to be ubiquitous 
distributed throughout the body and to play a central role in many cellular and physiological events 
[22]. Inhibition of the GSK-3β pathway has emerged as a potential therapeutic approach for a number 
of pathologies [23].
 In our continuing efforts to identify new protein kinase inhibitors for potential use 
as anticancer agents, a yeast glycogen synthase kinase-3β assay was adopted, to rapidly screen and 
identify candidate compounds that target serine/threonine and/or tyrosine kinases activities. 
The crude organic extract from Latrunculia sp. showed an inhibition of nitric oxide (NO) 
production in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells with an IC50 value of 16.6 μg/mL. 




epimuqubilin A (1) [14], muqubilone B (2) [24], unnamed cyclic peroxide ester (3) [25], epimuqubilin 
B (4) [14], sigmosceptrellin A methyl ester (5) [1,18], sigmosceptrellin A (6) [25], and 
sigmosceptrellin B methyl ester (7) [25]. Herein we report the isolation, structure elucidation, and 
biological activities of these compounds. Compounds 1–7 were also evaluated for their inhibitory 
activity in the yeast GSK-3β assay. 
2. Results and Discussion  
Seven cyclic peroxides (Figure 1) were isolated from an organic extract of Latrunculia sp. C006879 
and were tested for their NO inhibitory activity using RAW 264.7 cells. The results indicated 
epimuqubilin A (1) possessed potent NO inhibitory activity against lipopolysaccharide (LPS)-induced 
nitric oxide release with an IC50 value of 7.4 µM, followed by 6 (sigmosceptrellin A, IC50 = 9.9 µM), 
whereas other compounds exhibited activity with the IC50 values in the range of 23.8−65.7 µM. 
Sigmosceptrellin A methyl ester (5) was inactive in the NO inhibitory assay. The potency of 1 was 
comparable to that of L-N
G-monomethyl arginine citrate, a positive control (IC50 = 25.5 µM). All 
compounds showed no cytotoxicity at their IC50 values for NO inhibitory activity. Structure–activity 
relationships of these compounds against NO release indicated the following: (1) a monocyclic carbon 
skeleton framework was essential for activity as observed in 1 (IC50 = 7.4 µM) versus  2  
(IC50 = 23.8 µM), (2) a free acid gave higher activity than an ester, as observed in 6 (IC50 = 9.9 µM) 
versus 5 (IC50 >100 µM), (3) the orientation of H3-22 at an equatorial position increased activity, as 
observed in 7 (IC50 = 65.7 µM) versus 5 (IC50 > 100 µM), and (4) a bicyclic ring reduced activity, as 
observed in 6 (IC50 = 9.9 µM) versus 1 (IC50 = 7.4 µM).  
In addition, to determine whether the inhibitory effects of compounds on NO production were due 
to specific pharmacological activities, or non-specific cell cytotoxicity leading to false positive results, 
RAW 264.7 cell viability was determined by using the sulforhodamine B (SRB) protein staining 
method. Compounds 1 and 6 mediated a modest cytototoxic response, with 36.1 and 43.0% percent 
survival, respectively, at the highest concentration tested (20 µg/mL; 51.0 µM). Cytotoxic effects 
diminished with lower concentrations. Notably, at a concentration of 12.8 µM (above the IC50 values 
of compounds 1 and 6), no significant cytotoxic effects were observed. Further experiments will be 
performed to determine whether epimuqubilin A inhibits nitrite production via suppression of iNOS 
expression in the levels of protein. 
Compounds 1–7 were also evaluated for their inhibitory activities in the yeast GSK-3β assay at both 
25 and 37 °C. Compounds 1, 4, and 6 exhibited significant inhibitory activities against yeast GSK-3β 
plates (Table 1) and gave 10–13 mm zones of inhibition (ZOI) at 40 μg/disk. All other isolated 
compounds were inactive. The clear ZOI at 37 °C and no ZOI at 25 °C indicated the inhibition of  
GSK-3β pathway. Compounds 1, 4 and 6 exhibited potent inhibitory activity and gave 8 mm clear ZOI 
at 20 μg/disk at 37 °C and no ZOI at 25 °C, indicating that these compounds  inhibited GSK-3β 
pathway. Compound 6 appeared to be more potent as compared with 1, indicating that the presence of 
the bicyclic moiety was essential for activity.  
In this study, we found that epimuqubilin A (1) possessed potent NO production in LPS-stimulated 
RAW 264.7 cells and sigmosceptrellin A (6) exhibited significant of the selective GSK-3β pathway. 




Table 1. Biological activity of tested compounds on the NO inhibitory activity and the 






a (mm) at 37 °C 
(µg/disk) 
% Survival
b IC50, µM  40  20  10  5 
Epimuqubilin A (1) 7.4  36.1 37.1  10  9  na
c na 
Muqubilone B (2) 23.8  99.0 -  na  -  -  - 
Unnamed cyclic peroxide ester (3) 46.0  >100 -  nt
d -  -  - 
Epimuqubilin B (4) 25.6  >100 -  10  8  na  na 
Sigmosceptrellin A methyl ester (5) >100  90.6 -  na  -  -  - 
Sigmosceptrellin A (6) 9.9  43.0 42.7  13  11  10  8 
Sigmosceptrellin B methyl ester (7) 65.7  >100 -  na  -  -  - 
L-NMMA
e  25.5 >100 - -  -  -  - 
TDZD-8
f at 37 °C        15  11  10  9 
 at 25 °C        12  10  9  8 
a Diameter of disk alone is 7 mm. Stock solutions were prepared in either dimethyl sulfoxide (DMSO) or methanol 
(MeOH). No zones of inhibition were observed with DMSO or MeOH as negative controls. Active compounds were 
retested at lower concentrations (10–2.5 μg/disk). 
b % Survival was tested at 20 μg/mL after 20 h incubation in RAW 
264.7 cells. 
c Not active. 
d Not tested. 
e L-N
G-Monomethyl Arginine citrate (L-NMMA), non-selective inhibitor of NOS. 




Figure 1. Structures of compounds 1–7. 
  




Compounds  1,  2,  5, and 6 have been reported in treatment of human African trypanosomiasis 
against Trypanosoma brucei with IC50 values in the range of 0.2−2.0 μg/mL [25]. Compound 4 was 
isolated from the sponge Diacarnus megaspinorhabdosa and exhibited cytotoxic [5] and antimicrobial 
activities [25]. As described in the literatures, it was also observed that insertion of a prenyl unit in the 
central portion of the molecule made norsesterterpenes cyclic peroxides (compounds 1–7) more active 
than their norterpene congeners (diacarperoxide A-C) [5]. It has been reported previously that a longer 
side chain allowed the norsesterterpenes to cross cell membranes (lipophilicity effect) and afforded a 
better fit to the receptor (side effect) [26]. In another study, the cytotoxic and antiparasitic properties 
for 1,2-dioxane and furan ketides, isolated from the sponge Plakortis angulospiculatus [27], were 
compared. These results showed that both heterocyclic ring displayed modest cytotoxicity, while one 
of the 1,2-dioxane structures potently inhibited Leishmania chagasi and Trypanosoma cruzi. 
3. Experimental Section  
3.1. Test Compounds 
The sponge Latrunculia sp. (C006879) was collected at a depth of 15 m in the Indo-West Pacific 
(Indo-Polynesian), on September 6, 1990. The sponge was frozen immediately upon collection and 
shipped to NCI (National Cancer Institute, Frederick, MD). After aqueous extraction of the frozen soft 
corals at 4 °C, the extracts were lyophilized and extracted sequentially with CH2Cl2-MeOH (1:1) and 
MeOH. The combined organic extracts were evaporated in vacuo and stored at -30 °C. A voucher 
specimen was deposited at the National Museum of Natural History, Smithsonian Institution, 
Washington, D.C. 
A crude organic extract (3.0 g), provided by the NCI Natural Products Open Repository collection, 
exhibited NO inhibitory activity with an IC50 value of 16.6 μg/mL. This extract was chromatographed 
on silica gel (150 g) using CC eluting with the stepwise with hexanes–EtOAc (1:9 → 0:10, each  
200 mL), and EtOAc–MeOH (1:9 → 1:1, each 200 mL), respectively to afford seven fractions (F1-F7). 
Fraction F4 (744.4 mg) was further purified by reversed-phase CC (60 g) eluting with MeOH-H2O  
(3:2 → 0:10, each 100 mL) to give six subfractions (F4a-F4f). Compound 1 (5.6 mg) was isolated 
from subfraction F4b (30.4 mg) by recrystallization from MeOH-CHCl3 (1:1). Repeated reversed-
phase CC (10 g) with MeOH–H2O (3:2, 350 mL) on subfraction F4d (50.5 mg) gave compounds 2  
(3.2 mg), 3 (1.0 mg), 5 (5.8 mg) and 7 (3.6 mg). Subfractions F4f (19.2 mg) was subjected to   
RP-HPLC (10 μm, 10 x 250 mm, Econosil C18, 2.0 mL/min) eluting isocratically with MeOH-H2O 
(97:3) to afford compound 4 (5.6 mg, tR 24.6 min). Fraction F6 (377.1 mg) was purified by silica gel 
CC ( 10.0 g) eluting with acetone-hexanes (1:4 → 1:1, each 100 mL) to give compound 6 (2.2 mg).  
Epimuqubilin A (1): Colorless viscous oil; [α]
21
D  +55.9 (c 0.027, CHCl3); IR (film) νmax 3450, 2925, 
1710, 1578, 1320 cm
-1; ESIMS m/z 393.30 [M + H]
+. 
Muqubilone B (2): Colorless viscous oil; [α]
21
D +52.5 (c 0.002, CHCl3); IR (film) νmax 3422, 2953, 
1700, 1498, 1321 cm
-1; ESIMS m/z 425.30 [M + H]
+. 
Unnamed cyclic peroxide ester (3): Colorless viscous oil; [α]
21
D  -57.8 (c 0.013, CHCl3); IR (film) 
νmax 2967, 1670, 1530, 1134 cm
-1; ESIMS m/z 407.32 [M + H]
+.




Epimuqubilin B (4): Colorless viscous oil; [α]
21
D  + 15.8 (c 0.017, CHCl3); IR (film) νmax 3445, 2929, 
1685, 1540, 1130 cm
-1; ESIMS m/z 423.31 [M + H]
+. 
Sigmosceptrellin A methyl ester (5): Colorless viscous oil; [α]
21
D  +57.9 (c 0.001, CHCl3); IR (film) 
νmax 2935, 1665, 1434, 1150 cm
-1; ESIMS m/z 407.32 [M + H]
+.
 
Sigmosceptrellin A (6): Colorless viscous oil; [α]
21
D  +51.3 (c 0.027, CHCl3); IR (film) νmax 3380, 
2960, 1723, 1560, 1140 cm
-1; ESIMS m/z 393.30 [M + H]
+. 
Sigmosceptrellin B methyl ester (7): Colorless viscous oil; [α]
21
D  -55.4 (c 0.003, CHCl3); IR (film) 
νmax 2960, 1660, 1560, 1150 cm
-1; ESIMS m/z 407.32 [M + H]
+. 
3.2. Assay for NO inhibitory effect using RAW264.7 cells 
The inhibitory effects of samples on NO production were evaluated in LPS-activated murine 
macrophage RAW 264.7 cells, using a method modified from that previously reported [28]. Briefly, 
RAW 264.7 cells were cultured in Dulbecco's modified Eagle’s medium (DMEM) supplemented with 
penicillin G sodium (100 units/mL), streptomycin sulfate (100 µg/mL), amphotericin B (0.25 µg/mL), 
and 10% fetal bovine serum (FBS). The cells were seeded in 96-well culture plates with   
1 × 10
5 cells/well and incubated for 24 h at 37 °C in a humidified atmosphere containing 5% CO2. The 
cells were treated with samples dissolved in phenol red-free DMEM for 30 min followed by 1 µg/mL 
of LPS treatment for 20 h. The amount of NO in the cultured medium was measured by the Griess 
reagent. The standard curve was created by using known concentrations of sodium nitrite, and the 
absorbance was measured at 540 nm. To evaluate the cytotoxic effect of samples in RAW 264.7 cells 
in the assay condition, SRB assay was performed. Briefly, after the fixation with 10% trichloroacetic 
acid (TCA), cells were stained with 0.4% SRB solution in 1% acetic acid followed by dissolving 
bound SRB in 10 mM Tris-buffer. The optical density was determined at 515 nm. 
3.3. Glycogen synthase kinase-3β assay 
Disruption of four yeast GSK-3 homologs (MCK1, MDS1, MRK1 and YOL128C) in gsk-3 null 
mutant confers a temperature-sensitive phenotype (growth defect at 37 ºC), that can be suppressed by 
the expression of cloned mammalian GSK-3β [29]. Inhibition of GSK-3β should therefore mimic the 
phenotype of the gsk-3 null mutant, indicated by growth inhibition of transformant of gsk-3 null with 
pKT10-GSK-3β only at 37 ºC. A genetically modified yeast strain, H10075 with genotype {MATα 
his3  leu2 ura3 trp1 ade2 mck1::TRP1 mds1::HIS3 mrk1 yol128c::LEU2 [pKT10-GSK-3β], was 
grown in 5 mL of liquid media of SC minus uracil, shaking, at 37 ºC for 2 days. Four hundred-μL of 
the yeast culture was added to 100 mL of SC minus uracil agar [0.67% yeast nitrogen base without 
amino acids and ammonium sulfate, 0.5% ammonium sulfate, 2% D-(+)-glucose anhydrate, 1 mL each 
of 0.03 mg/mL of adenine (hemisulfate salt), 0.03 mg/mL of L-tryptophan, 0.03 mg/mL of L-leucine, 
0.03 mg/mL of L-histidine and 1.5% bacteriological agar, pH 5.6]. To perform the assay, compounds 
and extracts at a concentration of 80 μg per disk were dispensed on filter disks, and placed on plates 
containing yeast seeded into SC minus uracil media. The Petri dishes were incubated at both 25 ºC and 
37 ºC for 72 hours. Three phenotypes are observed on yeast plates. A clear zone of inhibition (ZOI) at 
37 ºC and no ZOI at 25 ºC indicate that the agent tested inhibits the GSK-3β pathway. The clear zones 




a negative phenotype are plates that have no observable ZOI. Active compounds were then tested at 
lower concentrations (40, 20, 10, 5 μg per disk). The assays were performed in duplicate. GSK-3β 
inhibitor (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione), and staurosporine were used as positive 
controls. 
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